13D Filings
Tempest Therapeutics, Inc.
TPST
Amendment
Ownership

4.80%

Total Shares

2,118,644

Issuer CIK

1544227

CUSIP

87978U108

Event Date

Nov 11, 2024

Accepted

Feb 11, 2025, 05:58 PM

Reporting Persons (9)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Versant Vantage II, L.P.
Partnership
4.80%2,118,6442,118,6440
Versant Vantage II GP-GP, LLC
Other
4.80%2,118,64402,118,644
Versant Vantage II GP, L.P.
Partnership
4.80%2,118,64402,118,644
Versant Ventures IV, LLC
Other
2.70%1,178,47101,178,471
Versant Venture Capital IV, L.P.
Partnership
2.70%1,171,0941,171,0940
Versant Ventures VI GP, L.P.
Partnership
0.50%209,9140209,914
Versant Venture Capital VI, L.P.
Partnership
0.50%209,914209,9140
Versant Ventures VI GP-GP, LLC
Other
0.50%209,9140209,914
Versant Side Fund IV, L.P.
Partnership
0.00%7,3777,3770
Disclosure Items (1)

Security Title

Common Stock, par value $0.001 per share

Issuer Name

Tempest Therapeutics, Inc.

Issuer Address

2000 Sierra Point Parkway, Brisbane, CA, 94005

Tempest Therapeutics, Inc. — Schedule 13D | 13D Filings